2024
Reasons for Declining Participation in Inpatient Research Among Historically Minoritized Racial and Ethnic Communities: A Scoping Review
Bavishi P, Grimshaw A, Perez O, Kiluk B, Edelman E. Reasons for Declining Participation in Inpatient Research Among Historically Minoritized Racial and Ethnic Communities: A Scoping Review. Contemporary Clinical Trials Communications 2024, 101386. DOI: 10.1016/j.conctc.2024.101386.Peer-Reviewed Original ResearchStudy burdenInpatient hospital settingSocial support networksSocial support systemsPhysician involvementScoping reviewRecruitment methodsInpatient settingPatient trustWeb of Science databasesDeclined participationRefusing participationEquitable recruitmentEthnicity dataHospital settingSupport networksRecruitment effortsRefusal reasonsInpatient stayStudy designInclusion criteriaEnhance participationDemographic informationCochrane LibraryClinical trialsGlobal Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database.
Alhajahjeh A, Rotter L, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database. JCO Global Oncology 2024, 10: e2400316. PMID: 39621951, DOI: 10.1200/go-24-00316.Peer-Reviewed Original ResearchAnalyzing determinants of premature trial discontinuation in leukemia clinical trials
Rotter L, Alhajahjeh A, Stempel J, Grimshaw A, Bewersdorf J, Blaha O, Kewan T, Podoltsev N, Shallis R, Mendez L, Stahl M, Zeidan A. Analyzing determinants of premature trial discontinuation in leukemia clinical trials. Leukemia & Lymphoma 2024, ahead-of-print: 1-9. PMID: 39440622, DOI: 10.1080/10428194.2024.2416565.Peer-Reviewed Original ResearchClinical trialsSlow accrualLeukemia trialsEarly-phase trialsNon-randomized trialsAcademic-sponsored trialsImprove patient outcomesLeukemia clinical trialsSingle-centerTrial discontinuationSponsored trialsSmall trialsLeukemiaEarly terminationPatient outcomesLate-phaseIndependent reviewersTermination ratesComprehensive searchTrials
2023
The global prevalence of human fascioliasis: a systematic review and meta-analysis
Infantes L, Yataco G, Ortiz-Martínez Y, Mayer T, Terashima A, Franco-Paredes C, Gonzalez-Diaz E, Rodriguez-Morales A, Bonilla-Aldana D, Barahona L, Grimshaw A, Chastain D, Sillau S, Marcos L, Henao-Martínez A. The global prevalence of human fascioliasis: a systematic review and meta-analysis. Therapeutic Advances In Infectious Disease 2023, 10: 20499361231185413. PMID: 37434654, PMCID: PMC10331341, DOI: 10.1177/20499361231185413.Peer-Reviewed Original ResearchHuman fascioliasisHigh prevalenceGlobal prevalenceSystematic reviewTropical diseasesLarger study sample sizeFollowing inclusion criteriaRandom-effects modelAppropriate diagnostic methodologyHigher prevalence estimatesWorld Health OrganizationRetrospective cohortCase seriesPooled prevalenceSignificant morbiditySubgroup analysisDisease burdenPrevalence proportionsClinical trialsJBI SUMARIWorldwide prevalenceStudy sample sizeInclusion criteriaMethodological qualityGeneral population
2022
Randomized Clinical Trials of Machine Learning Interventions in Health Care
Plana D, Shung DL, Grimshaw AA, Saraf A, Sung JJY, Kann BH. Randomized Clinical Trials of Machine Learning Interventions in Health Care. JAMA Network Open 2022, 5: e2233946. PMID: 36173632, PMCID: PMC9523495, DOI: 10.1001/jamanetworkopen.2022.33946.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsRisk of biasClinical trialsSystematic reviewNon-RCT designHealth careCONSORT-AIClinical adoptionCochrane riskOvid EmbaseCochrane LibraryTrial characteristicsOvid MEDLINEPrimary interventionExclusion criteriaCommon reasonMedian proportionPatient careRCT designLiterature searchOverall riskRelevant articlesLack of participantsTrialsGoogle Scholar
2021
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects modelRisk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta‐analysis
Holleck JL, Roberts AE, Marhoffer EA, Grimshaw AA, Gunderson CG. Risk of Intestinal Necrosis With Sodium Polystyrene Sulfonate: A Systematic Review and Meta‐analysis. Journal Of Hospital Medicine 2021, 16: 489-494. PMID: 34328838, DOI: 10.12788/jhm.3655.Peer-Reviewed Original ResearchConceptsSevere gastrointestinal side effectsGastrointestinal side effectsIntestinal necrosisHazard ratioSide effectsComposite outcomeOdds ratioSodium polystyrene sulfonateSystematic reviewSevere gastrointestinal adverse eventsGastrointestinal adverse eventsPooled hazard ratioRisk of biasPooled odds ratioCase-control studyPrior systematic reviewsSystematic literature searchAdverse eventsAlternative medicationsCochrane LibraryDatabase inceptionClinical trialsNecrosis rateInclusion criteriaPotential confounding
2020
Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors
Giri S, Grimshaw A, Bal S, Godby K, Kharel P, Djulbegovic B, Dimopoulos MA, Facon T, Usmani SZ, Mateos MV, Costa LJ. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors. JAMA Oncology 2020, 6: 1759-1765. PMID: 32970151, PMCID: PMC7516804, DOI: 10.1001/jamaoncol.2020.4338.Peer-Reviewed Original ResearchConceptsProgression-free survivalHigh-risk MMBackbone regimensRefractory MMHazard ratioMultiple myelomaClinical trialsSystematic reviewDerSimonian-Laird random-effects modelPhase 3 trialImproved response ratesPreferred Reporting ItemsRandom-effects modelCochrane riskSame regimenCytogenetic riskCochrane LibraryMeeting libraryI2 statisticImproved outcomesMAIN OUTCOMEThird investigatorCochran's QPatientsReporting Items
2019
Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimens